ASCO GU 2022 Highlights
The addition of sacituzumab govitecan (Trodelvy), an antibody–drug conjugate, to the PD-1 inhibitor pembrolizumab (Keytruda) showed encouraging antitumor activity in checkpoint inhibitor–naïve patients with metastatic urothelial cancer, according to an analysis of the results of cohort 3 from the phase 2 TROPHY-U-01 clinical trial, which were presented at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium by Petros Grivas, MD, PhD, Clinical Director, Genitourinary Cancers Program, University of Washington School of Medicine, Seattle; and Associate Professor, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle.
Continuous Treatment with Enzalutamide and Docetaxel Reduces the Risk for Progression in Patients with Metastatic Castration-Resistant Prostate Cancer
Continuous treatment with the androgen receptor inhibitor enzalutamide (Xtandi) in combination with docetaxel significantly improved progression-free survival (PFS) compared with placebo plus docetaxel in men with metastatic castration-resistant prostate cancer (mCRPC) whose disease progressed while receiving enzalutamide alone in the phase 3b PRESIDE clinical trial.
Neoadjuvant Enfortumab Vedotin Therapy Promising in Patients with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Neoadjuvant therapy with enfortumab vedotin (Padcev) showed promising antitumor activity in patients with MIBC who were ineligible for cisplatin therapy, based on the preliminary findings for cohort H from the phase 1b/2 EV-103 clinical trial.
Results 1 - 3 of 3